Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non‐resectable hepatocellular carcinoma tumours of ≥3 cm  by Jacob, Rojymon et al.
ORIGINAL ARTICLE
Adjuvant stereotactic body radiotherapy following transarterial
chemoembolization in patients with non-resectable hepatocellular
carcinoma tumours of ≥3 cm
Rojymon Jacob1, Falynn Turley2, David T. Redden2, Souheil Saddekni3, Ahmed K. A. Aal3, Kimberly Keene1, Eddy Yang1,
Jessica Zarzour4, David Bolus4, J. Kevin Smith4, Stephen Gray5, Jared White5, Devin E. Eckhoff5 & Derek A. DuBay5
1Department of Radiation Oncology, 2Biostatistics Division, School of Public Health, 3Interventional Oncology, Department of Radiology, 4Diagnostic Body
Radiology, Department of Radiology and 5Department of Liver Transplant and Hepatobiliary Surgery, University of Alabama at Birmingham, Birmingham,
Alabama, USA
Abstract
Objectives: The optimal locoregional treatment for non-resectable hepatocellular carcinoma (HCC) of
≥3 cm in diameter is unclear. Transarterial chemoembolization (TACE) is the initial intervention most
commonly performed, but it rarely eradicates HCC. The purpose of this study was to measure survival in
HCC patients treated with adjuvant stereotactic body radiotherapy (SBRT) following TACE.
Methods: A retrospective study of patients with HCC of ≥3 cm was conducted. Outcomes in patients
treated with TACE alone (n = 124) were compared with outcomes in those treated with TACE + SBRT
(n = 37).
Results: There were no significant baseline differences between the two groups. The pre-TACE mean
number of tumours (P = 0.57), largest tumour size (P = 0.09) and total tumour diameter (P = 0.21) did not
differ significantly between the groups. Necrosis of the HCC tumour, measured after the first TACE, did
not differ between the groups (P = 0.69). Local recurrence was significantly decreased in the TACE + SBRT
group (10.8%) in comparison with the TACE-only group (25.8%) (P = 0.04). After censoring for liver
transplantation, overall survival was found to be significantly increased in the TACE + SBRT group
compared with the TACE-only group (33 months and 20 months, respectively; P = 0.02).
Conclusions: This retrospective study suggests that in patients with HCC tumours of ≥3 cm, treatment
with TACE + SBRT provides a survival advantage over treatment with only TACE. Confirmation of this
observation requires that the concept be tested in a prospective, randomized clinical trial.
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Introduction
The optimal locoregional treatment of hepatocellular carcinoma
(HCC) of <3 cm in diameter is tumour ablation.1–4 The optimal
locoregional treatment for HCC of ≥3 cm, however, is less clear.
According to the Barcelona Clinic Liver Cancer (BCLC) treatment
algorithm, transarterial chemoembolization (TACE) is the recom-
mended treatment for intermediate-stage HCC in patients who
are not candidates for surgical resection or tumour ablation.3,4
Current guidelines from the American Association for the
Study of Liver Diseases (AASLD) and National Comprehensive
Cancer Network (NCCN) also recommend TACE as therapy for
unresectable HCC.1,2,5 Randomized clinical trials published in the
early 2000s comparing TACE with the provision of best support-
ive care reported 2-year survival rates ranging between 31% and
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63%.6,7 However, TACE rarely completely sterilizes the HCC
tumour and thus it is considered a palliative, life-prolonging
therapy.8
Stereotactic body radiotherapy (SBRT) is a rapidly evolving
therapeutic option for inoperable HCC. Improved imaging
methods for localizing HCC lesions and precise treatment plan-
ning facilitate the delivery of targeted radiation with minimal
treatment of uninvolved tissue.9 By contrast with conventional
algorithms for the delivery of radiotherapy that stipulate the
administration of small doses of radiation spread over several
weeks, SBRT involves the precision delivery of a highly focused
dose of radiation to the target tumour over a short number of
treatments. For example, a common regimen for the delivery of
conventional radiotherapy for liver tumours involves the delivery
of treatment on 5 days per week over 5 weeks to give a total dose
of 50 Gy, whereas a common SBRT regimen would stipulate the
delivery of 15 Gy per treatment for a total of three treatments,
delivered over 7 days.
Emerging data indicate promising results with the use of SBRT,
with 1-year local control rates ranging between 80% and 87% and
median survival of 17–19 months.10,11 However, although the
NCCN5 recommends SBRT as a possible alternative to TACE for
unresectable tumours, this treatment modality is not mentioned
in the AASLD1,2 or BCLC3,4 treatment algorithms. The use of SBRT
in the treatment of locally advanced HCC has been reported pri-
marily from centres in Asia, where the incidence of HCC is
high.10–14 Stereotactic body radiotherapy has been used in various
contexts, including as sole therapy, following incomplete TACE
and as a salvage treatment for tumour recurrence following other
treatments.10–14 The reported outcomes of this treatment vary in
these heterogeneous populations and many of the studies were
uncontrolled case series.
Stereotactic body radiotherapy was initiated at the University
of Alabama at Birmingham (UAB) as a palliative therapy for
unresectable HCC, typically in patients for whom no other
therapeutic options were available. After surprisingly good
clinical outcomes, the centre began to treat select patients in
whom HCC persisted after TACE with SBRT as destination
therapy and occasionally as bridging therapy for waitlisted liver
transplant candidates. There are several potential oncologic
advantages of using TACE followed by SBRT. Transarterial
chemoembolization is most effective at the centre of the HCC.
Failures most commonly occur at the periphery of the HCC
tumour, where the ischaemic effects of TACE are least potent
because the surrounding uninvolved liver parenchyma is well
oxygenated. By contrast, radiation is most effective in the well-
oxygenated periphery of the HCC tumour and failures tend to
occur in the more hypoxic areas at the centre of the tumour.
Large tumours that are not suitable for SBRT alone become
more amenable to this therapy following TACE of the tumour
centre. In addition, a theoretical radio-sensitization by the
cytotoxic agents used in TACE may bring about an improved
tumour response.15
The purpose of this study was to measure the outcomes
obtained by using TACE alone with those achieved by using
a combination of TACE followed by SBRT in patients with
unresectable HCC of ≥3 cm in diameter. The study hypothesis
assumed that survival would be superior in patients treated with a
combination of TACE and SBRT compared with that in those
treated with TACE alone.
Materials and methods
Ethics approval for this study was obtained from the UAB
Institutional Review Board (protocol no. X100310006). A
retrospective chart review was performed for all HCC patients
treated with TACE at UAB between January 2008 and August
2013.
Patient population
Patients were diagnosed with HCC according to the AASLD
criteria either by biopsy or by the presentation of classic HCC
radiologic features.1,2 The decision to offer TACE and SBRT to
patients with HCC was made by a multidisciplinary liver tumour
board at UAB, which included diagnostic radiology faculty
members, pathologists, medical oncologists, radiation oncolo-
gists, surgeons, hepatologists and interventional radiologists.
A list of all HCC patients treated with TACE as a first
locoregional oncologic therapy was generated from the UAB
interventional radiology procedures electronic database (n = 262).
Data for patients with an HCC tumour of <3 cm in size (n = 69)
and for those in whom an ablation had been performed after the
TACE procedure (n = 42) were excluded (Fig. 1). Tumours of
HCC that had previously been treated operatively or with another
locoregional therapy such as radiofrequency ablation or external
beam radiotherapy were excluded from the study. Patients taking
chemotherapeutic agents before and/or after the procedure were
included in the study.
Transarterial chemoembolization procedures were performed
as previously described.16,17
Protocol for SBRT
Patients underwent four-dimensional computed tomography
(CT) simulation following immobilization in the supine posi-
tion. Oral and i.v. contrast materials were administered during
the procedure. Computed tomography images were transferred
to a computerized treatment planning system. Gross tumour
volume (GTV) encompassed all visible disease on contrasted CT
simulation. Clinical target volume (CTV) included an additional
4 mm around the tumour. The planned target volume (PTV)
was constructed by adding a 5-mm geometric uncertainty
margin around the CTV. The dose–volume constraints used
during SBRT planning are fairly standardized: care was taken to
ensure that at least 700 cm3 of normal liver parenchyma was
exposed to <15 Gy over the course of SBRT, consistent with pub-
lished recommendations.18 Patients were treated on a linear
HPB 141
HPB 2015, 17, 140–149 © 2014 International Hepato-Pancreato-Biliary Association
accelerator with respiratory gating. Cone-beam CT, orthogonal
imaging and a real-time tracking technique were used for image
guidance according to standard practice in the department at the
time of treatment. The typical prescription dose was 45 Gy
administered in three fractions to the PTV. All patients were
premedicated with oral anti-nausea medications prior to SBRT.
All patients underwent blood counts and liver function testing,
and were evaluated clinically for SBRT-related toxicities during
the course of their treatment and at periodic intervals thereafter
(Fig. 2).
Radiographic measurements
Diagnosis of HCC
Hepatocellular carcinoma is diagnosed according to the visuali-
zation of an arterially enhancing lesion of 1–2 cm in size with
portal venous washout and a pseudocapsule on delayed-phase
CT, or the visualization of an arterially enhancing lesion of
>2 cm in size with portal venous washout or a pseudocapsule on
delayed-phase CT.19,20
Necrosis of the HCC tumour
Tumour response was assessed via the modified response
evaluation criteria in solid tumours (mRECIST) as previously
described.17 There are four categories of tumour response accord-
ing to mRECIST, which indicate: complete response; partial
response; stable disease, and progressive disease.21
Sarcopoenia
Psoas cross-sectional area was used as a surrogate marker of fra-
gility.22 The area of the right and left psoas muscle was measured
at the level of the fourth lumbar vertebral body on cross-sectional
imaging. The enclosed region was then used to calculate the cross-
sectional area of the psoas muscle.
262 HCC patients
treated with TACE
during 2008–2013
Data for 69 patients with HCC
of < 3 cm excluded
Data for 42 patients treated with
TACE and ablation excluded
161 patients with
HCC of ≥ 3 cm
treated with TACE
124 patients treated with TACE alone 37 patients treated with TACE + SBRT
Figure 1 Inclusion and exclusion criteria used to select patients for this retrospective study from among 262 patients with hepatocellular
carcinoma (HCC) treated with protocols including transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT)
▶
Figure 2 (a) Axial computed tomography (CT) scan demonstrating a hepatocellular carcinoma (HCC) lesion treated with lipiodol-based
transarterial chemoembolization (TACE). (b) Axial CT scan obtained 4 months after TACE plus stereotactic body radiotherapy (SBRT)
illustrating significant HCC tumour (and surrounding tissue) involution. (c) Axial CT SBRT plan showing highly conformal dose distribution
around the target. (d) Coronal CT SBRT plan showing highly conformal dose distribution around the target. (e) Gross pathologic photo-
graph of an HCC specimen obtained at the time of liver transplantation from a patient treated with TACE + SBRT. (f) Histopathology
of the HCC specimen in (e) demonstrates complete tumour necrosis and no viable HCC. (Haematoxylin and eosin stain; original
magnification ×4)
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Cirrhosis
A modified caudate to right lobe ratio of >0.9,23,24 nodular trans-
formation of the liver and sequela of portal venous hypertension25
were used as radiographic indicators of cirrhosis.
Data analysis
Data on patient demographics, clinical history, laboratory find-
ings and HCC tumour characteristics were collected. Liver disease
was quantified according to the Model for End-stage Liver Disease
(MELD) score and Child–Pugh score. Pre-TACE variables col-
lected by CT and magnetic resonance imaging (MRI) included
number of lesions, size of tumours and the total diameter of the
three largest tumours in patients with multifocal HCC. Tumour
stage was measured according to BCLC staging, including
BCLC-B subtypes.26 Data collected from post-TACE CT and MRI
included HCC tumour necrosis as measured according to
mRECIST criteria.21 To allow the use of common statistical pro-
cedures, the analysis was restricted to examination of the index
HCC tumour, which was defined as the largest tumour. (The use
of more than one tumour per patient in the analysis would have
violated the common assumption of independent data observa-
tions.) The hepatoma–arterial embolization (HAP) score27 was
used as a prognostic tool to compare outcomes following
initial TACE interventions between groups. The Assessment for
Retreatment with TACE (ART) score28 was used as a prognostic
tool to enable the comparison of outcomes following repeat TACE
interventions between groups.
A two-sample t-test was used to compare means between
groups. The primary analytic approach for dichotomous variables
utilized chi-squared analyses. Kaplan–Meier curves were con-
structed to evaluate patient survival. Survival probabilities were
analysed using the Wilcoxon test because it is more sensitive in
detecting differences at shorter survival times. Observations were
censored at the time of surgical resection or transplantation. For
all inferences, the probability of a type I error (α) was set at 0.05.
All analyses were conducted using sas Version 9.2 (SAS Institute,
Inc., Cary, NC, USA).
Results
Patient demographics
A total of 161 patients with HCC tumours of ≥3 cm treated with
TACE as an initial locoregional oncologic therapy were identi-
fied. Only TACE was used in 124 HCC patients, and TACE fol-
lowed by SBRT was used in 37 HCC patients. There were no
significant differences in age, gender, race or the aetiology of
liver disease between the TACE-alone and TACE + SBRT groups
(Table 1). Although all patients had underlying liver disease,
12.9% of the TACE-alone group and 16.2% of the TACE + SBRT
group did not have obvious cirrhosis as evidenced by platelet
counts of >100 and failure to meet cirrhosis cross-sectional
imaging characteristics. There were no significant differences in
underlying liver function as measured by the MELD score,
Child–Pugh score, BCLC-B subtype classification, or in muscle
wasting as quantified by sarcopoenia measurements. Further-
more, there were no differences between the groups in the pre-
dictors of TACE outcomes as quantified by the HAP and ART
scores (Table 1).
Tumour characteristics
There were no significant differences in α-fetoprotein measure-
ments between the TACE-alone and TACE + SBRT groups.
Tumour characteristics, as quantified by pretreatment cross-
sectional imaging, were also comparable between the groups
(Table 2). The mean ± standard deviation (SD) number of
tumours (2.1 ± 1.6 in the TACE-alone group and 1.8 ± 1.1 in the
TACE + SBRT group; P = 0.6), and distribution of unifocal and
multifocal HCC (52.9% and 47.1%, respectively, in the TACE-
alone group, and 54.1% and 45.9%, respectively, in the TACE +
SBRT group; P = 1.0) were nearly identical between groups. There
was a trend towards an increased size of the largest HCC tumour
in the TACE + SBRT group (5.8 ± 3.0 cm in the TACE-alone group
and 6.1 ± 2.4 cm in the TACE + SBRT group; P = 0.09), although
the total tumour diameter was nearly identical in both groups (7.7
± 4.9 cm in the TACE-alone group and 7.8 ± 3.3 cm in the TACE
+ SBRT group; P = 0.2). There were no significant differences in
the mRECIST measures of HCC tumour necrosis following initial
TACE (P = 0.7) (Table 2).
Sorafenib was used in 36.1% of TACE-alone patients and 41.9%
of TACE + SBRT patients (P = 0.7). Liver resection was performed
infrequently in the TACE-alone group and not at all in the TACE
+ SBRT group. Liver transplantation was performed in 15.5% of
the TACE-alone group and 12.1% of the TACE + SBRT group
(P = 0.8) (Table 2).
Transarterial chemoembolization procedures
The usage of lipiodol and drug-eluting beads (DEBs)-based TACE
was similar between groups (P = 0.7). Further, the total number
of TACE procedures administered was similar between groups
(P = 0.9) (Table 2).
Stereotactic body radiotherapy procedures
The characteristics of SBRT treatment and associated toxicities are
detailed in Table 3. Most patients were treated with one (n = 18) or
two (n = 15) TACE procedures prior to SBRT. Generally, SBRT was
started within 2 weeks of TACE, although in three patients the
interval between TACE and SBRT was >3 weeks. Respiratory
gating was employed during SBRT in all but three patients, in
whom the PTV excursion was not large enough to warrant its use.
Sorafenib was not administered concurrently in any patient. Rates
of SBRT-related toxicities were low; only one instance each of
Grade 2 and Grade 3 gastrointestinal toxicity occurred. No patient
developed Grade 2 or higher haematologic toxicities, and one
patient developed significant rib pain following treatment. One
patient died within 4 weeks following SBRT; the cause of
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death was presumed to reflect pulmonary sepsis rather than
radiation-induced liver disease (RILD).
Local recurrence and patient survival
Local recurrences were observed in 32 of 124 (25.8%) patients in
the TACE-alone group and in four of 37 (10.8%) patients in the
TACE + SBRT group (P = 0.042) (Table 2). There was no 30-day
mortality in either the TACE-alone or the TACE + SBRT group.
Data for 90-day mortality reflected the deaths of seven patients
in the TACE-alone group and none in the TACE + SBRT group
(P = 0.35). After censoring for liver transplantation, Kaplan–Meier
curves were constructed for each group (Fig. 3). Superior survival
was observed in the TACE + SBRT group compared with the
TACE-alone group (Wilcoxon test, P = 0.02). Median survival
estimated from the Kaplan–Meier curves was 20 months in the
TACE-alone group and 33 months in the TACE + SBRT group.
Discussion
This retrospective study suggests a survival advantage for patients
with HCC tumours of ≥3 cm treated with TACE + SBRT over
TACE alone. Patients treated with SBRT following TACE experi-
enced a median survival 13 months longer than that of patients
treated with TACE alone. The SBRT was well tolerated; no deaths
as a result of RILD and no instances of significant morbidity were
observed (toxicities: Grade 4, n = 0; Grade 3, n = 1; Grade 2, n = 2;
Grade 1, n = 145). These favourable survival outcomes observed
with TACE + SBRT support the supposition that the respective
strengths and weaknesses of TACE and SBRT are complementary:
TACE preferentially induces central HCC tumour necrosis and
SBRT preferentially treats the periphery of the HCC tumour.
Interestingly, although the initial analysis included HCC
tumours of all sizes treated with TACE and SBRT, smaller
HCC tumours did not appear to derive a survival advantage.
Table 1 Baseline demographics of patients with hepatocellular carcinoma of ≥3 cm treated with transarterial chemoembolization (TACE)
alone or TACE plus stereotactic body radiotherapy (SBRT)
Variable TACE-only group (n = 124) TACE + SBRT group (n = 37) P-value
Age, years, mean ± SD 62.2 ± 9.0 64.4 ± 12.7 0.405
Male, % 75.8% 72.8% 0.829
Race, % 0.494
Black 16.7% 21.6%
White 75.8% 75.7%
Other 7.5% 2.7%
Aetiology of liver diseasea, %
Alcohol 24.4% 18.9% 0.657
HBV 7.3% 8.1% 1.000
HCV 44.7% 51.4% 0.5733
NASH 20.2% 18.9% 1.000
Haemochromatosis 2.4% 5.4% 0.324
Portal hypertensionb, % 0.862
Platelet count ≤ 100, cirrhosis 46.0% 46.0%
Platelet count > 100, cirrhosis 41.1% 37.8%
Platelet count > 100, no cirrhosis 12.9% 16.2%
Sarcopoenia measurement, cm2, mean ± SD 10.6 ± 3.4 11.2 ± 3.8 0.247
MELD score, mean ± SD 11.2 ± 4.2 10.2 ± 3.6 0.211
Child–Pugh score, mean ± SD 6.7 ± 1.5 6.3 ± 1.2 0.291
HAP score, mean ± SD 1.2 ± 0.8 1.3 ± 0.9 0.525
BCLC-B subtypes, % 0.287
B1 22.0% 16.7%
B2 36.4% 55.6%
B3 13.6% 8.3%
B4 28.0% 19.4%
ART score, mean ± SD 1.3 ± 1.7 1.6 ± 2.1 0.923
aSome patients had liver disease of more than one aetiology.
bCirrhosis diagnosis is based upon cross-sectional imaging characteristics.
ART, Assessment for Retreatment with TACE; BCLC, Barcelona Clinic Liver Cancer; HAP, hepatoma–arterial embolization; HBV, hepatitis B virus; HCV,
hepatitis C virus; MELD, Model for End-stage Liver Disease; NASH, non-alcoholic steatohepatitis; SD, standard deviation.
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Exploratory correlation analysis suggested a survival advantage in
tumours of ≥3 cm. Clinical practice at the study centre favours the
ablation of HCC lesions of <3 cm unless these HCC tumours are
in an unfavourable position (adjacent to major biliary structures)
or in patients with significant comorbidities. Thus the lack of a
survival advantage in HCC lesions of <3 cm may reflect a negative
selection bias, or it may be that the additive effects of SBRT are
only observed when HCC tumours have achieved a certain size.
The mechanism of improved survival may simply derive from
improved local control as evidenced by the significantly lower rate
of local recurrence observed in the TACE + SBRT group.
Although more technically difficult to administer than other
forms of radiotherapy, SBRT is more simple and expeditious for
the patient and is predicted to be more clinically efficacious than
conventional radiotherapy approaches.29 Unlike conventional
radiotherapy schedules in which treatment is administered on 5
days per week for 5–6 weeks, SBRT in this study was predomi-
nately delivered in three fractions of 15 Gy over a 7-day period.
Such a regimen is attractive to patients who must travel long
distances and increases the likelihood that patients will receive
radiotherapy at a centre with hepatobiliary expertise. Treatment
with SBRT also spares more uninvolved liver parenchyma from
high-dose radiation compared with conventional radiotherapy,
which is very important given that 85–95% of cases of HCC in
Western centres arise in the setting of cirrhosis.1,2 Two recent
meta-analyses (consisting almost exclusively of studies from
Eastern centres) have looked at the outcomes of combining TACE
with different forms of radiotherapy (but not SBRT).30,31 The
meta-analyses concluded that there was a significant improve-
ment in overall survival with the use of TACE combined with
radiation therapy.30,31 This improvement in survival was achieved
without an incremental increase in the rate of serious adverse
effects.30,31
An alternative interpretation of the present data is that SBRT
alone provided the survival advantage, not the TACE + SBRT. Case
series without concurrent comparison control groups have
reported in-field tumour control rates of up to 90% in select HCC
patients using SBRT alone.11,13,32 Consistent with BCLC recom-
mendations, the protocol at the present centre typically starts with
the administration of TACE in non-resectable HCC lesions of
Table 2 Tumour and treatment characteristics in patients with hepatocellular carcinoma (HCC) of ≥3 cm treated with transarterial
chemoembolization (TACE) alone or TACE plus stereotactic body radiotherapy (SBRT)
Variable TACE-only group (n = 124) TACE + SBRT group (n = 37) P-value
α-fetoprotein, ng/ml, mean ± SD 19.8 ± 192.1 32.7 ± 456.0 0.534
Tumour characteristics
Number of tumours, mean ± SD 2.1 ± 1.6 1.8 ± 1.1 0.571
HCC type, % 1.000
Unifocal disease 52.9% 54.1%
Multifocal disease 47.1% 45.9%
Size of largest tumoura, cm, mean ± SD 5.8 ± 3.0 6.1 ± 2.4 0.094
Total tumour diameterb, cm, mean ± SD 7.7 ± 4.9 7.8 ± 3.3 0.206
Response according to mRECISTc, % 0.688
Complete 27.2% 30.3%
Partial 52.2% 57.6%
Stable 13.0% 9.1%
Progressive 7.6% 3.0%
Sorafenib pre- or post-d, % 36.1% 41.9% 0.677
Type of TACE, % 0.707
Lipiodol 54.8% 59.5%
Drug-eluting beads 42.7% 40.5%
TACE treatments, n, mean ± SD 1.3 ± 0.6 1.3 ± 0.7 0.906
Curative interventions, %
Liver resection 6.7% 0% 0.348
Liver transplantation 15.5% 12.1% 0.784
Local recurrence,% 25.8% 10.8% 0.042
aAxial diameter of largest tumour.
bSum of axial diameters of three largest lesions.
cTumour necrosis measurements are from 30 days post-TACE.
dSorafenib use defined as within 90 days pre- or post-TACE.
SD, standard deviation.
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≥3 cm.3,4 Furthermore, for destination therapy, it is the current
institution’s practice to combine different locoregional modalities
when it is feasible to do so to improve outcomes, given the fre-
quent local failure rates of TACE alone and radiotherapy alone.
Another aspect of HCC treatment that is unresolved by these
data concerns the size limits and characteristics of the HCC
tumour that can be effectively treated by TACE in combination
with SBRT. Is there a cut-off size after which TACE + SBRT is no
longer effective? What impact does segmental or lobar venous
vascular invasion have? Kang et al. reported a study conducted in
Seoul, South Korea, in which 47 patients with inoperable HCC
achieved a 76.6% rate of complete or partial response to salvage
SBRT following one to five TACE procedures.12 In this case series,
the HCC lesions measured up to 10 cm in greatest axial diameter
and 25% of tumours demonstrated portal venous invasion.12 This
study highlights the promising results of combining TACE and
SBRT, even in large tumours with unfavourable characteristics.
The present authors also have anecdotal experience of a handful of
HCC patients with major vascular invasion or tumour thrombus
who have exceeded their expected survival after treatment with
TACE + SBRT.
The accurate localization of and delivery of radiation to the
HCC tumour in SBRT is technologically demanding. One of the
biggest technical challenges refers to localizing the tumour using
orthogonal kV (static plain film) imaging or cone-beam CT
(unenhanced) prior to treatment delivery. The practice of the
present authors is to use either lipiodol-based TACE or radio-
opaque fiducials in patients in whom adjuvant SBRT is planned.
The lipiodol is radio-opaque and can be identified to some extent
on plain films, but especially well on unenhanced CT. In TACE
patients treated with DEBs, this group has employed percutane-
ous placement of radio-opaque fiducials (Polymark 1 × 3 mm;
Cortex Manufacturing, Inc., Portland, OR, USA). Typically, three
fiducials are placed near the tumour prior to CT simulation.
Simulation scans are used to generate a digitally constructed
radiograph, which also depicts the lipiodol contrast or fiducials in
relationship to the HCC tumour. Lipiodol or fiducials are identi-
fied by imaging at the time of SBRT. By overlaying the current
image on the digitally constructed ‘planning’ radiograph by apply-
ing shifts along the x-, y- and z-axes, the targets on the two images
(the digitally reconstructed ‘planning’ image and the real-time
image) are made to overlap precisely, thereby allowing the very
accurate delivery of radiotherapy to planned fields. Modern radio-
therapy treatment machines are capable of synchronizing radia-
tion delivery with preselected phases of the patient’s respiratory
cycle (‘respiratory gating’), thereby further improving accuracy.
Various studies to evaluate newer methods of target delineation,
such as real-time fiducial tracking, as well as refinements in radia-
tion techniques, such as ‘radiation dose-painting’, in an effort to
improve treatment delivery and limit toxicities are currently
ongoing.33,34
As with all retrospective studies, this report has limitations. Of
greatest concern is the potential patient selection bias. This refers
to the question of whether the patients selected to receive SBRT
simply represented a group of patients who were expected to do
better, which might explain the apparent survival advantage of
TACE + SBRT. To address this concern, the present authors
planned to use propensity scores to match covariates in the
TACE-alone and TACE + SBRT groups. However, the covariates
Table 3 Characteristics and toxicities of stereotactic body radio-
therapy (SBRT) in patients with hepatocellular carcinoma also
treated with transarterial chemoembolization (TACE)
Patients, n
SBRT patients 37
TACE procedures
1 18
2 15
3 or more 4
Time from TACE to SBRT
≤2 weeks 28
2–3 weeks 6
>3 weeks 3
Respiratory gating
Yes 34
No 3
Use of fiducials
Yes 9
No 28
Duration of SBRT
≤7 days 21
8–9 days 9
≥10 days 7
SBRT dose
36 Gy in three fractions 3
45 Gy in three fractions 26
60 Gy in three fractions 3
Others 5
Toxicities
Gastrointestinal
Grades 0 and 1 35
Grade 2 1
Grade 3 1
Haematologic
Grades 0 and 1 37
Bone and soft tissue
Grades 0 and 1 36
Grade 2 1
Hepatic
Grades 0 and 1 37a
aOne death occurred 4 weeks following SBRT as a result of pulmonary
sepsis.
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did not differ significantly between the groups at baseline
(Tables 1 and 2), thus eliminating the need for propensity
scores.35 From a clinical perspective, some faculty members in the
UAB tumour clinic were supportive of adjuvant SBRT, whereas
others had concerns regarding the efficacy of this therapy. Refer-
rals for adjuvant SBRT ebbed and flowed according to the suc-
cesses and failures of this treatment modality. These practice
patterns account for much of the dispersion of patients between
the TACE-alone and TACE + SBRT groups. However, it is likely
that patient selection bias can only be conclusively addressed in a
randomized clinical trial. Other limitations of this report include
its retrospective design, the fact that it represents a single-centre
experience, and the relatively small number of patients treated
with TACE + SBRT. Despite these limitations, the present data
represent one of the largest experiences (and one of the very few
controlled series) of HCC patients treated with TACE + SBRT at
a Western centre.
In conclusion, this retrospective study suggests a survival
advantage for patients with HCC tumours of ≥3 cm treated with
TACE + SBRT over TACE alone. The confirmation of this obser-
vation will require this concept to be tested in a prospective,
randomized clinical trial.
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